

CITATION REPORT

List of articles citing

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

DOI: 10.1007/s40268-020-00311-6
Drugs in R and D, 2020, 20, 171-187.

Source: <https://exaly.com/paper-pdf/77064028/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Hepatitis C. <i>Physician Assistant Clinics</i> , 2021 , 6, 555-568	0.2	
2	Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions. <i>Dermatologic Clinics</i> , 2022 ,	4.2	
1	Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2. 2022 , 309, 121048		1